Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of Meropenem-Vaborbactam on the QT/QTc Interval in Healthy Volunteers

NCT03564158 is registered in ClinicalTrials.gov with Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.) as lead sponsor.

NCT NCT03564158
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03564158 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of Meropenem-Vaborbactam on the QT/QTc Interval in Healthy Volunteers
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Phase
Phase 1
Overall status
Completed
Start date
May 1, 2018
Completion date
November 19, 2018
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy